Semaglutide reduces cardiovascular events by 20% in overweight or obese adults who don't have diabetes: Trial
Findings from a multi-center, international clinical trial reported by a Cleveland Clinic physician show that semaglutide reduced cardiovascular events by 20% in adults with overweight or obesity and established cardiovascular ...
Nov 13, 2023
0
97